Krystal Biotech, Inc. (KRYS)
Stock Price:
$40.12 USD
-1.06 (-2.57%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
788.92M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-20.32M |
| Shares Out |
17.39M |
| EPS (ttm) |
-1.24 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$40.12 |
| Previous Close |
$41.18 |
| Change ($) |
-1.06 |
| Change (%) |
-2.57% |
| Day's Open |
41.00 |
| Day's Range |
40.00 - 42.56 |
| Day's Volume |
165,472 |
| 52-Week Range |
31.89 - 66.85 |
More Stats
| Market Cap |
788.92M |
| Enterprise Value |
605.43M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.39M |
| Float |
13.54M |
| EPS (basic) |
-1.24 |
| EPS (diluted) |
-1.24 |
| FCF / Share |
-1.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.58M |
| Short Ratio |
7.74 |
| Short % of Float |
10.61% |
| Beta |
1.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.96 |
| Revenue |
n/a |
| Operating Income |
-23.33M |
| Net Income |
-20.32M |
| Free Cash Flow |
-27.93M |
| Net Cash |
183.49M |
| Net Cash / Share |
9.33 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-5.83% |
| ROE |
-8.58% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$78.25*
(95.04% upside)
Low
64.0
Current: $40.12
High
100.0
Target: 78.25
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -22.08 | -11.92 | -4.77 | -1.14 |
| Net Income | -19.09 | -10.89 | -7.92 | -1.15 |
| Shares Outstanding | 15.90 | 11.20 | 5.36 | 0.88 |
| Earnings Per Share | -1.20 | -0.97 | -1.48 | -1.31 |
| Operating Cash Flow | -18.71 | -9.45 | -3.89 | -1.31 |
| Capital Expenditures | -6.40 | -2.23 | -0.21 | -0.02 |
| Free Cash Flow | -25.11 | -11.68 | -4.10 | -1.33 |
| Cash & Equivalents | 194 | 112 | 49.59 | 1.92 |
| Total Debt | 3.26 | - | - | 1.84 |
| Net Cash / Debt | 190 | 112 | 49.59 | 0.08 |
| Assets | 209 | 116 | 50.11 | 2.18 |
| Liabilities | 6.11 | 2.89 | 0.64 | 1.89 |
| Book Value | 203 | 113 | 49.47 | 0.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Krystal Biotech, Inc. |
| Country |
United States |
| Employees |
51 |
| CEO |
Krish S. Krishnan |
Stock Information
| Ticker Symbol |
KRYS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KRYS |
| IPO Date |
September 20, 2017 |
Description
Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.